Evidence map›Paper›PMID 41768813›Full record

ReviewJNMA; journal of the Nepal Medical Association2025

Comparative Effectiveness of Omeprazole and Lansoprazole in Gastroesophageal Reflux Disease (GERD): A Review Article.

Rizky Gustinanda, Febby Zulkarnain, Merry Permatasari, Adonia Citra Farciana

Abstract readReviewComparative Study
In one paragraph

Review in JNMA; journal of the Nepal Medical Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rizky GustinandaFaculty of Pharmacy, Ahmad Dahlan University, Campus III Soepomo, Warungboto, Umbulharjo, Yogyakarta, Postal Code 55164, Indonesia.
Febby ZulkarnainFaculty of Pharmacy, Sanata Dharma University, Campus III Paingan, Maguwoharjo, Depok, Sleman, Yogyakarta, Postal Code 55281, Indonesia.
Merry PermatasariFaculty of Pharmacy, Sanata Dharma University, Campus III Paingan, Maguwoharjo, Depok, Sleman, Yogyakarta, Postal Code 55281, Indonesia.
Adonia Citra FarcianaFaculty of Pharmacy, Sanata Dharma University, Campus III Paingan, Maguwoharjo, Depok, Sleman, Yogyakarta, Postal Code 55281, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review discusses the use of Omeprazole and Lansoprazole as therapy in patients with Gastroesophageal Reflux Disease (GERD). GERD is a digestive tract disorder caused by repeated reflux of stomach contents into the esophagus. GERD is often characterized by symptoms of a burning and burning chest (heartburn). The most widely used pharmacological therapy to treat GERD is Proton Pump Inhibitor (PPI) drugs, such as Omeprazole and Lansoprazole with a working mechanism that inhibits the proton pump that H+ ions exit from the gastric parietal cells. The method used in writing this article review is an electronic literature study by accessing national and international journal search sites. The results obtained are based on effectiveness, Omeprazole is more effective and faster in reducing and maintaining gastric acid pH. Based on the adverse effects of the drug, Omeprazole has a lower potential risk of causing diarrhea. Omeprazole has the most minimal cost analysis when viewed from the cost aspect and Omeprazole has a faster onset than Lansoprazole.

Indexed as

Gastroesophageal RefluxLansoprazoleOmeprazoleProton Pump InhibitorsHumansTreatment OutcomeLansoprazoleOmeprazoleProton Pump Inhibitorsdrug effectivenessgastroesophageal reflux diseaselansoprazoleomeprazole

Identifiers

PMID41768813
PMCPMC12750982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.